Suchergebnisse - "Antineoplastic Agents"

PubPharm (14.256)

1

Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for Breast Cancers

enthalten in: Monoclonal antibodies in immunodiagnosis and immunotherapy | 2024

von Kaneko, M. | Suzuki, H. | Kato, Y.

ErratumIn: Monoclon Antib Immunodiagn Immunother. 2024 Apr 16;:. - PMID 38625004

2

Antibody-Drug Conjugates in Triple Negative Breast Cancer

enthalten in: Clinical breast cancer | 2024

von Keskinkilic, M. | Sacks, R.

3

Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients

enthalten in: Clinical and translational medicine | 2024

von Massa, C. | Karn, T. | Weber, K. | +19

4

Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer

enthalten in: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | 2024

von Smesseim, I. | Mets, O. | Daniels, J. | +2

5

Antibody drug conjugates in breast cancer in China : Highlights, challenges, and prospects

enthalten in: Cancer | 2024

von Li, J. | Jiang, Z.

6

Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer

enthalten in: Cancer | 2024

von Qu, F. | Lu, R. | Liu, Q. | +4

7

A nanomedicine composed of polymer-ss-DOX and polymer-Ce6 prodrugs with monoclonal antibody targeting effect for anti-tumor chemo-photodynamic synergetic therapy

enthalten in: Acta biomaterialia | 2024

von Yu, L. | Zhang, M. | He, J. | +2

8

Rethinking strategies in SCLC : Lessons learned from tiragolumab in the SKYSCRAPER-02 study

enthalten in: Med (New York, N.Y.) | 2024

von Laguna, J. | Mezquita, L.

9

Selective activation of IFNγ-ipilimumab enhances the therapeutic effect and safety of ipilimumab

enthalten in: International journal of biological macromolecules | 2024

von Huang, Y. | Ho, K. | Cheng, T. | +8

10

Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model

enthalten in: Clinical & experimental metastasis | 2024

von Pourjamal, N. | Yazdi, N. | Halme, A. | +5

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[1426]